<DOC>
	<DOCNO>NCT01454934</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , Phase 3 study , compare efficacy safety eribulin TPC subject advanced disease progression follow least two prior regimen advance disease , include platinum-based regimen .</brief_summary>
	<brief_title>A Randomized , Open-label , Multicenter , Phase 3 Study Compare Efficacy Safety Eribulin With Treatment Physician 's Choice Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>Inclusion : Subjects must meet follow criterion include study : 1 . Histologically cytologically confirm diagnosis NSCLC . 2 . Documented evidence advance NSCLC amenable surgery radiotherapy . 3 . Confirmation presence absence EGFR mutation prior study enrolment subject . 4 . Subjects must receive least two prior regimen advance NSCLC , include platinumbased regimen , subject tumor harbour EGFR mutation , EGFR TKI . 5 . Radiographic evidence disease progression , , last anticancer regimen prior study entry . 6 . Presence measurable disease . 7 . ECOG performance status 0 , 1 , 2 . 8 . Adequate bone marrow 9 . Adequate renal function . 10 . Adequate liver function . 11 . Female subject childbearing potential must agree use two form highly effective contraception . 12 . Male subject female partner childbearing potential must agree use two form highly effective contraception . 13 . Voluntary agreement provide write informed consent willingness ability comply aspects protocol . 14 . Males female age least 18 year ( age great 18 year determine country legislation ) time informed consent . Exclusion : Subjects meet follow criterion exclude study : 1 . Subjects receive anticancer therapy within 14 day , five halflives drug ( whichever longer ) , prior randomization . 2 . Subjects recover toxicity result prior anticancer therapy less Grade 2 . 3 . Subjects previously treat , participate study eribulin , whether treat eribulin . The TPC option must include agent subject receive prior regimen . 4 . Peripheral neuropathy CTCAE Grade 2 . 5 . Significant cardiovascular impairment . 6 . Subjects high probability Long QT Syndrome , QTc interval &gt; 500 ms. 7 . Subjects brain subdural metastasis eligible , unless metastasis asymptomatic require treatment adequately treat local therapy . 8 . Any serious concomitant illness . 9 . Known HIV positive , infection require treatment . 10 . Any malignancy require treatment , show evidence recurrence ( except NSCLC , nonmelanoma skin cancer , histologically confirm complete excision carcinoma insitu ) 5 year prior study entry . 11 . Female subject must pregnant , must breastfeed . 12 . Hypersensitivity either HalB HalB chemical derivative , excipients eribulin formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>